Anika Therapeutics Stock Today
| ANIK Stock | USD 17.71 0.28 1.61% |
PerformanceVery Weak
| Odds Of DistressLow
|
Anika Therapeutics is selling for 17.71 as of the 25th of February 2025. This is a 1.61 percent increase since the beginning of the trading day. The stock's last reported lowest price was 17.33. Anika Therapeutics has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 25th of February 2025. Click here to learn more.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company has 14.65 M outstanding shares of which 385.1 K shares are presently shorted by private and institutional investors with about 6.18 trading days to cover. More on Anika Therapeutics
Moving against Anika Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Anika Stock Highlights
Anika Therapeutics (ANIK) is traded on NASDAQ Exchange in USA. It is located in 32 Wiggins Avenue, Bedford, MA, United States, 01730 and employs 357 people. Anika Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 255.27 M. Anika Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 14.65 M outstanding shares of which 385.1 K shares are presently shorted by private and institutional investors with about 6.18 trading days to cover.
Anika Therapeutics currently holds about 87.78 M in cash with (1.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01.
Check Anika Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Anika Therapeutics is $255.27 Million. The majority of Anika Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Anika Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Anika Therapeutics. Please pay attention to any change in the institutional holdings of Anika Therapeutics as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Anika Ownership Details
Anika Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Anika Therapeutics market risk premium is the additional return an investor will receive from holding Anika Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0141 | |||
| Jensen Alpha | 0.0035 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.0025 |
Anika Stock Against Markets
Anika Therapeutics Corporate Management
| Ian McLeod | VP Officer | Profile | |
| James Chase | Senior Marketing | Profile | |
| Bart Bracy | VP Americas | Profile | |
| Lisa Funiciello | Vice Resources | Profile | |
| Mark Namaroff | Executive Communications | Profile | |
| Michael CPA | Executive Officer | Profile | |
| Charles III | VP Counsel | Profile |
Already Invested in Anika Therapeutics?
The danger of trading Anika Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Anika Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Anika Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Anika Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.